ADAP Adaptimmune Therapeutics plc

5.16
-0.2  -4%
Previous Close 5.36
Open 5.27
Price To Book 1.96
Market Cap 539583517
Shares 104,570,449
Volume 371,414
Short Ratio
Av. Daily Volume 663,546

SEC filingsSee all SEC filings

  1. 8-K - Current report 181230081
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181161974
  3. 8-K - Current report 181161501
  4. 8-K - Current report 181131595
  5. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 181116129

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Oral presentation at CTOS November 9, 2017.
NY-ESO T-cell therapy
Synovial sarcoma - cancer
Reported no clinical responses October 2016. Intends to alter dosage to include fludarabine.
NY-ESO T-cell therapy
Ovarian cancer
Phase 1/2 presentation at SITC November 2018.
NY-ESO T-cell therapy
Myxoid round cell liposarcoma (MRCLS)
Updated data at ASH December 2017 - Overall response rate (ORR) at 100 days and one year were 76% and 44%.
NY-ESO T-cell therapy
Myeloma
Phase 1/2 initiated November 2015. Data are due 2017.
NY-ESO T-cell therapy
Non-small cell lung cancer (NSCLC)
Phase 1 data at ESMO noted best response was 4/6 with stable disease.
MAGE-A4
Soild tumors
Dose escalation to Cohort 2 in early 2019.
AFP
Hepatocellular carcinoma
Phase 1 data at ESMO noted no current response.
MAGE-A10
Non-Small Cell Lung Cancer (NSCLC)

Latest News

  1. Adaptimmune Announces that Gwen Binder will leave in January 2019
  2. Recent Analysis Shows Bellicum Pharmaceuticals, NetEase, Nice, Match Group, SpartanNash, and Adaptimmune Therapeutics Market Influences — Renewed Outlook, Key Drivers of Growth
  3. Edited Transcript of ADAP earnings conference call or presentation 6-Nov-18 1:00pm GMT
  4. uniQure Stock Rose 35.7% Yesterday—Here’s Why
  5. What You Must Know About Adaptimmune Therapeutics plc’s (NASDAQ:ADAP) Financial Strength
  6. Adaptimmune Reports Third Quarter 2018 Financial Results and Business Update
  7. Adaptimmune to Report Third Quarter 2018 Financial Results and Business Update on Tuesday, November 6, 2018
  8. 3 Beaten-Down Biotech Stocks: Can They Bounce Back?
  9. Adaptimmune Therapeutics Worldwide Enters Oversold Territory
  10. Adaptimmune's stock tumbles after cancer study results prompts price target cut
  11. Updated Data from Ongoing MAGE-A10 and MAGE-A4 Studies Presented at the 2018 ESMO Congress
  12. Investor Expectations to Drive Momentum within Arsanis, Dynavax Technologies, Puma Biotechnology, Opko Health, Adaptimmune Therapeutics, and Codexis — Discovering Underlying Factors of Influence
  13. Data Updates from Ongoing MAGE-A10 Studies and MAGE-A4 Study to be presented at the European Society for Medical Oncology (ESMO) 2018 Congress
  14. 3 Biotech Stocks That Big Investors Are Snatching Up
  15. Should You Be Holding Adaptimmune Therapeutics plc (NASDAQ:ADAP) Right Now?
  16. Adaptimmune Therapeutics Rose 21% in Week Ended August 24
  17. Options Traders Expect Huge Moves in Adaptimmune (ADAP) Stock

SEC Filings

  1. 8-K - Current report 181230081
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181161974
  3. 8-K - Current report 181161501
  4. 8-K - Current report 181131595
  5. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 181116129
  6. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 181115832
  7. SC 13D - General statement of acquisition of beneficial ownership 181073388
  8. 8-K - Current report 181059559
  9. 8-K - Current report 181053920
  10. 424B5 - Prospectus [Rule 424(b)(5)] 181053916